Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA Clinical Trial Steering Committee and Investigators

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Fingerprint

Dive into the research topics of 'Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences